G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

19 Jul 2021 09:20:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Jul 2021 19:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors

18 Jun 2021 09:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

16 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

14 Jun 2021 07:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2021 16:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

04 Jun 2021 09:02:41 By Nasdaq GlobeNewswire

G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

04 Jun 2021 09:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

19 May 2021 17:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer

17 May 2021 07:00:02 By Nasdaq GlobeNewswire

G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)

10 May 2021 06:50:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 May 2021 16:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights

05 May 2021 16:01:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021

28 Apr 2021 10:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)

28 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer

26 Apr 2021 09:41:56 By Nasdaq GlobeNewswire

G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

07 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021

01 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology

25 Mar 2021 06:50:00 By Nasdaq GlobeNewswire